INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

More and better kinds of screening as well as new, more targeted treatments are making breast cancer less deadly.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and contributing significantly to cancer-related mortality globally.

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

These findings indicate that this system is suitable for detecting differential interaction of a bait protein (p18) with two different prey proteins (cdk4, cdk6). A partial screen of a cDNA ...

Our preliminary data revealed that PD-1, an immune checkpoint protein, is involved in the resistance to one chemotherapeutic, CDK4/6 inhibitor. We investigate the efficacy of a combination of ...

epigenetic regulation and the role of the unfolded protein response within tumor progression. One major focus of Dr. Diehl’s research concerns the mechanisms whereby growth-signaling pathways regulate ...